Media Release: BigDNA awarded SMART innovation grant from Scottish Enterprise

BIGDNA, the vaccine development company based at Roslin Biocentre outside Edinburgh, today announced that it has been awarded a SMART: Scotland innovation grant from Scottish Enterprise, Scotland’s main economic development agency.

Says a spokesperson: “These grants are awarded to Scottish-based companies developing innovative technologies with high potential for growth and economic benefit.

“BigDNA received the maximum award available in that round, which was £70,000, as part of the overall project investment of £103,406.”

Commenting on the award, Dr John March, chief executive Officer of BigDNA, said that this grant would enable the company to develop the ‘second generation’ form of its proprietary bacteriophage-based platform technology.

Dr March added: “The platform will underpin a new pipeline of vaccine candidate products targeting infectious disease indications of high unmet medical and commercial need – we are delighted that Scottish Enterprise has recognised the potential in this technology.”

Michael Cannon, head of Innovation Grants at Scottish Enterprise, commented: “BigDNA is a great example of an ambitious Scottish company keen to maximise its business growth opportunities.

“Scotland continues to produce exciting innovative young companies with emerging technology, products and services that boast global potential and we want to see more of them access the wide range of support we have to offer at Scottish Enterprise.”


This information from: Carol Anderson, The Business tel 0131 718 6022

E: mobile 07836 546 256

About BigDNA

BigDNA is a preclinical stage vaccine development company focused on the development of a proprietary vaccine development platform based on modified bacteriophage (phage).

The platform technology has a number of key benefits in that it acts as a potent immunostimulator/adjuvant, is able to be administered via a variety of routes and is easy and rapid to manufacture.

The company is developing a portfolio of vaccine candidates targeting diseases of high unmet medical and commercial need.

MEDIA RELEASE posted by The Business PR. You too can post media releases (aka press releases) on For more information, email here.

Website: http://www.